Sorbent series B reaches $53M with Novartis Venture on board
This article was originally published in Scrip
Executive Summary
Sorbent Therapeutics, a private US company developing therapies for cardiovascular and renal disorders, has expanded its series B financing from September 2010 by $36 million. This brings the total proceeds to $53 million. New investor Novartis Venture Funds led this financing, joining existing investors Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem.